CRISPR THERAPEUTICS AG (NASDAQ:CRSP) Files An 8-K Other EventsItem 8.01. Other Events
On December7, 2017, CRISPR Therapeutics AG issued a press release announcing the submission of a Clinical Trial Application for CTX001 in ß-thalassemia. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 8.01. Financial Statements and Exhibits.
CRISPR Therapeutics AG ExhibitEX-99.1 2 d504564dex991.htm EX-99.1 EX-99.1 EXHIBIT 99.1 CRISPR Therapeutics Submits First Clinical Trial Application for a CRISPR Gene-Edited Therapy,…To view the full exhibit click
About CRISPR THERAPEUTICS AG (NASDAQ:CRSP)
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell. The location at which the Cas9 molecular scissors cut the DNA to be edited is specified by guide ribonucleic acid (RNA), which is comprised of a crRNA component and a tracrRNA component, either individually or combined together as a single guide RNA. The Company has business operations in London, the United Kingdom, as well as research and development operations in Cambridge, the United States.